Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 3Phase 2 3Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 1Glioblastoma 1Depression 1Anxiety Disorders 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Niacin × Clear all
NCT04677049 2026-01-02

Study of Niacin in Glioblastoma

AHS Cancer Control Alberta

Phase 1/2 Suspended
59 enrolled
CNS

Glioblastoma

NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡